Joan Tymon-Rosario

Joan Tymon-Rosario

Auto-generated profile, based on publicly available information

Joan Tymon-Rosario

Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
BZBurak Zeybek
Burak Zeybek
AMARANZAZU MANZANO
ARANZAZU MANZANO
ABAnna Bianchi
Anna Bianchi
EBElena Bonazzoli
Elena Bonazzoli
SBStefania Bellone
Stefania Bellone
ASAlessandro Santin
Alessandro Santin
Human trophoblast cell-surface marker (Trop-2) is a surface glycoprotein originally identified in human placental tissue and subsequently found to be highly expressed by various types of human epithelial solid tumors. We investigated the efficacy of sacituzumab govitecan, an antibody-drug conjugate (ADC) comprised of a humanized anti- Trop-2 antibody, conjugated with active metabolite of irinotecan (SN-38), on Trop-2 positive cervical cancer cell lines and a xenograft model. Trop-2 expression was evaluated in 147 primary cervical tumors by immunohistochemistry, real-time polymerase chain reaction, and flow cytometry. For in vitro experiments, two Trop-2 positive (CVX-8, ADX-3), and one Trop-2 negative (ADX-2) cell lines were used. A cell line with a strong Trop-2 expression (CVX-8) was used to test in vivo antitumor activity in xenografts models. Out of 147 primary cervical cancers, 113 were squamous cell carcinomas (SCCs), and 34 were adenocarcinoma/adenosquamous carcinomas. Moderate to strong diffuse staining was seen in 95% (108/113) of SCCs, and 81% (29/34) of adenocarcinoma/adenosquamous cancers on immunohistochemistry. Trop-2 positive cell lines were highly sensitive to sacituzumab govitecan in vitro, with IC50 values in the range of 0.18 to 0.26 nM (p = 0.02, and p = 0.04 for CVX-8, and ADX-3, respectively). In xenografts, a significant tumor growth inhibition was seen after twice-weekly intravenous administration of the drug for three weeks (p < 0.0001, and p = 0.001 for sacituzumab govitecan vs naked antibody, and sacituzumab govitecan vs control-ADC, respectively). Overall survival at 90 days was significantly improved in the sacituzumab govitecan group (p = 0.014). In conclusion, sacituzumab govitecan may represent a novel targeted therapy option in cervical cancer patients overexpressing Trop-2.

12 February 2020 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
Emanuele PerroneEmanuele Perrone
Emanuele Perrone
SLSalvatore Lopez
Salvatore Lopez
BZBurak Zeybek
Burak Zeybek
SBStefania Bellone
Stefania Bellone
EBElena Bonazzoli
Elena Bonazzoli
ASAlessandro Santin
Alessandro Santin
Background: Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy. Sacituzumab govitecan (SG) is a novel antibody-drug-conjugate (ADC) targeting trophoblast-antigen-2 (Trop-2), a cell surface glycoprotein highly expressed in many epithelial tumors, to deliver SN-38, the active metabolite of irinotecan. This study aimed to evaluate Trop-2 expression in EOC tissues and the preclinical activity of SG against primary EOC cell lines and xenografts. Methods: Trop-2 expression was assessed in 90 formalin-fixed-paraffin-embedded tumors and nine primary tumor cell lines by immunohistochemistry (IHC) and flow cytometry, respectively. Trop-2 expression and cell viability after exposure to SG in primary tumor cell lines, non-targeting control ADC, and SG-parental antibody hRS7 were evaluated using flow-cytometry-based-assays. Antibody-dependent-cell-cytotoxicity (ADCC) against Trop-2+ and Trop-2– EOC cell lines was tested in vitro using 4 h Chromium-release-assays. In vivo activity of SG was evaluated against Trop-2+ EOC xenografts. Results: Moderate-to-strong staining was seen in 47% (42/90) of ovarian tumors by IHC while 89% (8/9) of the primary EOC cell lines overexpressed Trop-2 by flow cytometry. EOC Trop-2+ were significantly more sensitive to SG compared to control ADC (p < 0.05). Both SG and hRS7 mediated high ADCC activity against Trop-2+ cell lines. SG also induced significant bystander killing of Trop-2– tumor cells admixed with Trop-2+ EOC cells. In in vivo experiments SG treatment demonstrated impressive anti-tumor activity against chemotherapy-resistant EOC xenografts. Conclusion: SG demonstrates remarkable preclinical activity against biologically aggressive and chemotherapy-resistant EOC cell lines and a significant bystander effect against EOC cell lines with heterogenous Trop-2 expression. Clinical trials are warranted.

31 December 2019 in Molecular Oncology
Verified
Journal Article
Open access
PDF file
Emanuele PerroneEmanuele Perrone
Emanuele Perrone
PMPaola Manara
Paola Manara
SLSalvatore Lopez
Salvatore Lopez
SBStefania Bellone
Stefania Bellone
EBElena Bonazzoli
Elena Bonazzoli
ASAlessandro Santin
Alessandro Santin
Endometrial cancer is the most common gynecologic malignancy in developed countries. The antibody–drug conjugate (ADC) sacituzumab govitecan (SG) targets trophoblast cell‐surface antigen‐2 (Trop‐2) – a cell‐surface glycoprotein highly expressed in many epithelial tumors – and delivers the active metabolite of irinotecan SN‐38 to Trop‐2‐positive tumor cells. We evaluated Trop‐2 expression in endometrial endometrioid carcinoma (EC) tissues and the activity of SG against primary poorly differentiated EC cell lines and xenografts. Trop‐2 expression was assessed in 143 formalin‐fixed–paraffin‐embedded tumors and seven primary tumor cell lines by immunohistochemistry and flow cytometry, respectively. Cell viability of primary tumor cell lines was assessed following exposure to SG, or control antibodies. Antibody‐dependent cell cytotoxicity (ADCC) against Trop‐2‐positive and Trop‐2‐negative EC cell lines was measured in vitro using 4‐h chromium release assays. A Trop‐2‐positive EC xenograft model was used to determine the in vivo activity of SG. Moderate‐to‐strong staining was detected in 84% (120/143) of EC samples, whereas 43% (3/7) of the primary EC cell lines tested overexpressed Trop‐2. EC cell lines overexpressing Trop‐2 were significantly more sensitive to SG compared to control ADC (P = 0.014 and P = 0.005). Both SG and the unconjugated parental antibody hRS7 mediated high ADCC against Trop‐2‐positive cell lines. Moreover, SG induced significant bystander killing of Trop‐2‐negative tumors cocultured with Trop‐2‐positive tumors. In the xenograft model, intravenous administration of SG twice weekly for three weeks was well tolerated and demonstrated impressive tumor growth inhibition against poorly differentiated, chemotherapy‐resistant EC xenografts (P = 0.011). In summary, SG is a novel ADC with remarkable preclinical activity against poorly differentiated EC cell lines overexpressing Trop‐2. These findings warrant future clinical trials.

4 February 2020 in Oncotarget
Verified
Journal Article
Open access
PDF file
SLSalvatore Lopez
Salvatore Lopez
Emanuele PerroneEmanuele Perrone
Emanuele Perrone
SBStefania Bellone
Stefania Bellone
EBElena Bonazzoli
Elena Bonazzoli
BZBurak Zeybek
Burak Zeybek
ASAlessandro Santin
Alessandro Santin
Oncotarget | https://doi.org/10.18632/oncotarget.27342 Salvatore Lopez, Emanuele Perrone, Stefania Bellone, Elena Bonazzoli, Burak Zeybek, Chanhee Han, Joan Tymon-Rosario, Gary Altwerger, Gulden Menderes, Anna...

1 February 2020 in Gynecologic Oncology
Verified
Journal Article
Closed access
CHChanhee Han
Chanhee Han
Emanuele PerroneEmanuele Perrone
Emanuele Perrone
BZBurak Zeybek
Burak Zeybek
SBStefania Bellone
Stefania Bellone
JTJoan Tymon-Rosario
Joan Tymon-Rosario
ASAlessandro Santin
Alessandro Santin

1 January 2021 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
BZBurak Zeybek
Burak Zeybek
EWEmily Webster
Emily Webster
NPNatalia Pogosian
Natalia Pogosian
JTJoan Tymon-Rosario
Joan Tymon-Rosario
ABAlan Balch
Alan Balch
VAVaagn Andikyan
Vaagn Andikyan
Zeybek B, et al. J Gynecol Oncol. 2021 Jul;32:e87. https://doi.org/10.3802/jgo.2021.32.e87